[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100634388":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":7,"centralContacts":8,"locations":14,"responsibleParty":39,"collaborators":7,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":7,"eligibilityCriteria":46,"healthyVolunteers":43,"sex":47,"minAge":48,"maxAge":7,"enrollmentInfo":49,"targetDuration":7,"studyType":52,"phases":7,"briefSummary":53,"conditions":54,"keywords":7,"overallStatus":17,"whyStopped":7,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},{"fullName":5,"class":6},"Centro di Riferimento Oncologico - Aviano","OTHER",null,[9],{"name":10,"role":11,"phone":12,"phoneExt":7,"email":13},"Mattia Garutti","CONTACT","0434659092","mattia.garutti@cro.it",[15],{"facility":16,"status":17,"city":18,"state":19,"zip":20,"country":21,"countryCode":22,"cosmosGeoPoint":23,"geoPoint":28,"contacts":29},"Centro di Riferimento Oncologico di Aviano","RECRUITING","Aviano","Pordenone","33081","Italy","IT",{"type":24,"coordinates":25},"Point",[26,27],12.59472,46.07056,{"lat":27,"lon":26},[30,32,34,37],{"name":31,"role":11,"phone":12,"phoneExt":7,"email":13},"Mattia Garutti, MD",{"name":31,"role":33,"phone":7,"phoneExt":7,"email":7},"PRINCIPAL_INVESTIGATOR",{"name":35,"role":36,"phone":7,"phoneExt":7,"email":7},"Linda Cucciniello, MD","SUB_INVESTIGATOR",{"name":38,"role":36,"phone":7,"phoneExt":7,"email":7},"Fabio Puglisi, MD, PhD",{"type":40,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100634388","effects-of-physical-activity-in-early-stage-hormone-receptor-positive-breast-cancer-patients-100634388",false,"NCT07539038","Effects of Physical Activity in Early Stage Hormone Receptor Positive Breast Cancer Patients","Inclusion Criteria:\n\n* Patients with early stage (I-IIIa) hormone receptor-positive breast cancer receiving adjuvant endocrine therapy\n* Female patients ≥18 years of age\n* Written informed consent must be obtained before any study-related assessment is performed\n* Participation to the Medicina and Sport physical activity program organized by Andos Pordenone\n\nExclusion Criteria:\n\n* Patients with early hormone receptor negative breast cancer\n* Patients with early hormone receptor positive breast cancer receiving chemotherapy\n* Patients with advanced\u002Fmetastatic breast cancer.\n* Patients receiving active treatment for secondary primary tumors (excluding basal cell carcinoma or in situ neoplasias).\n* Patients with history of vertebral and\u002For femoral fractures\n* Patients with CVDs not optimally controlled by medical therapy","FEMALE","18 Years",{"count":50,"type":51},44,"ESTIMATED","OBSERVATIONAL","The advances in early detection coupled with improvements in treatments have led to an ever-increasing number of breast cancer survivors. New methods to improve outcomes, including strategies aimed at improving the quality of life and reducing the risk of other diseases, may represent valid additions to the currently available treatment options. Interventions targeting diet, weight and physical activity can reduce the risk of cancer occurrence, prevent cancer recurrence, improve survival and the quality of life.\n\nThis is an observational, prospective study aimed at evaluating the effects of physical activity on the quality of life of patients with early stage hormone receptor positive breast cancer receiving adjuvant hormonal therapy and adhering to a physical activity program lasting for a total of 12 weeks organized by ANDOS onlus (Associazione Italiana Donne Operate al Seno).",[55],"Breast Cancer","2026-04-13",{"date":58,"type":59},"2026-04-20","ACTUAL",{"date":61,"type":59},"2025-04-03",{"date":63,"type":51},"2027-12-31",{"name":5,"class":6},1]